Albert VilellaIn #JPM2023 news, $RXRX Recursion Bio presented on January 10th, 2023 and the slides were made available for everyone to peruse. Initial slide portrays the Moore's Law vs Eroom's Law, and the opportunity for Compute-based Drug Discovery.
And yes, Illumina still produces microarray kits, even though these don't make it into the slide decks and presentations of the company in #JPM2023. In the methylation segment, Illumina started many years ago with a 27k array for human samples, which grew to the 450k array later.
Another entity that made a big splash at #JPM2023 was InstaDeep, which in collaboration with Nvidia and TUM is creating s genomic language model to understand DNA function.
In #JPM2023, $NAUT Nautilus Bio didn't make their slides available, but they have a slide deck from an investor meeting in December 2022. They intend to launch their Proteome Analysis Platform in Mid-2024.
In #JPM2023 news, $SEER also presented. They are another of the Next Generation Proteomics Sequencing players. One of their USPs is that they have an approach capable of finding different protein variants that would be undistinguishable with affinity-based approaches.
In #JPM2023 news, $AZTA Azenta also presented. They acquired Genewiz a few years ago, and they continue looking at M&A to consolidate their positioning, especially in Services for Life Sciences.
In #JPM2023 news, $OLK Olink presented and showed good numbers, especially for their high-plex segment.
In #JPM2023 news, $QSI Quantum-SI also presented on January 12, 2023. The company launched their Platinum protein sequencer a few weeks ago.
In #JPM2023 news, $ABSI Absci presented on Thursday 12, 2023. Also following the trend of asking AI what they should do, the company's Chief Morale Officer was put to the task of discovering biologics on a computer. Well, DALL-E's interpretation of that was on a slide.